Cholesterol Drug Tied to Sleep Disturbances

But Zocor, a statin, still offers significant heart benefits, researchers say

By Amanda Gardner
HealthDay Reporter

Related Encyclopedia • Abdominoplasty • Acidophilus • Alzheimer's Disease • Aneurysms More... Related Healthscout Videos Nutrition and Cancer Nutrition and Osteoporosis Importance of Good Nutrition Controlling Incontinence More... Related Animations • Alzheimer's Disease Video Animation • Angioplasty • Coronary Bypass Surgery • Erectile Dysfunction More... Related Drug Information • Accupril • Actonel • Altace • Avapro More... Related News Articles • Semi-Annual Time Changes May Affect the Heart • FDA Faulted for Stance on Chemical in Plastics • Family Halloween Safety Can Be Fiendishly Simple • Kidney Patients More Susceptible to Sudden Cardiac Death More...

WEDNESDAY, Nov. 7 (HealthDay News) -- Lowering your cholesterol could interrupt your slumber.

A new report found that the statin Zocor disrupts sleep patterns in some users.

Text Continues Below

---

"The study suggests that simvastatin [Zocor] is more likely to have sleep disruption," said Dr. Sidney Smith, past president of the American Heart Association and director of the Center for Cardiovascular Science and Medicine at the University of North Carolina School of Medicine. "The extent to which this would be a significant problem for patients is uncertain, but this should raise awareness that symptoms could be related to therapy."

The findings were presented Wednesday at the American Heart Association's annual meeting, in Orlando, Fla.

A growing number of Americans now take statins to reduce their cholesterol levels, as a way to prevent heart attack or stroke.

"There had long been concerns about statins adversely affecting sleep in case reports and case series dating back to at least 1990, just after the release of statins," said study author Dr. Beatrice Golomb, of the University of California, San Diego, School of Medicine's Department of Medicine. "The rub is that they used sample sizes that were tiny and follow-ups of only four to six weeks. The sample sizes were less than 20 or 30 -- not enough typically to show an effect unless the effect was huge," Golomb noted.

The new study, funded by the U.S. National Institutes of Health, is the largest of its kind and involved 1,106 healthy adult men and women who were randomly chosen to receive 20 milligrams of Zocor (simvastatin), 40 milligrams of Pravachol (pravastatin), or a placebo for six months. The two dosages of the two statins are considered approximately equivalent.

"We were looking at the impact of the most hydrophilic [Pravachol] and most lipophilic [Zocor] statins on a range of non-cardiac endpoints with sleep as a pre-specified secondary outcome," Golomb explained.

Page:  1 | 2 | Next >>